

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CF PharmTech, Inc.**  
**長風藥業股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2652)**

**VOLUNTARY ANNOUNCEMENT**  
**SUBMISSION OF MARKETING AUTHORIZATION APPLICATION FOR**  
**CF017 IN A SOUTHEAST ASIAN MARKET**

This announcement is made by CF PharmTech, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Group has recently submitted a marketing authorization application (the “**Application**”) for CF017), a budesonide suspension for inhalation, to the relevant drug regulatory authority in a Southeast Asian market.

CF017 was approved by the National Medical Products Administration of the People's Republic of China in May 2021 and has since been commercialized in China. Southeast Asia, with its large and growing population, rising healthcare demand and increasing prevalence of respiratory diseases, represents a market with significant potential for high-quality inhaled formulations. The Company believes that the submission of marketing authorization applications for CF017 in the Southeast Asian market marks a further step in the Group's global strategy to extend its international commercialization footprint.

**RISK WARNING**

The submission of marketing authorization applications is an administrative step in the regulatory review process and does not constitute marketing approval. The Application remains subject to review and assessment by relevant regulatory authority in the applicable jurisdiction, and there is no assurance that it will ultimately be approved. Given the inherent risks and uncertainties associated with pharmaceutical registration, regulatory approval and commercialization in overseas markets, **shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

## **ABOUT THE COMPANY**

As a global innovator in inhalation drug delivery technology, CF PharmTech, Inc. is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is not only a specialist in the development of complex inhalation formulations with high barriers to entry, but also a platform-based innovative pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, global regulatory filing and commercialization.

Leveraging its fully self-developed, globally integrated end-to-end capabilities – from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to siRNA nucleic acid delivery platforms – the Company is systematically advancing its proprietary innovative pipeline for the markets in China, the United States and Europe. Its therapeutic areas encompass respiratory diseases (including asthma, chronic obstructive pulmonary disease and bronchiectasis) and nasal diseases (including allergic rhinitis and chronic rhinosinusitis), with strategic expansion into pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections and central nervous system disorders, as the Company advances precision drug delivery via the nose-to-brain pathway.

The Company has established an extensive multi-dimensional commercialization network in China and, through its globally compliant manufacturing systems and deepening global presence, is steadily advancing towards its goal of becoming a global innovative pharmaceutical enterprise.

By order of the Board

**CF PharmTech, Inc.**

長風藥業股份有限公司

**Dr. LIANG Bill Wenqing**

*Chairperson, Executive Director and Chief Executive Officer*

Hong Kong, May 28, 2026

*As at the date of this announcement, the Board comprises Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi and Ms. ZHU Yuyu as executive Directors, Mr. CHEN Penghui, Mr. CAI Lei and Dr. YI Hua as non-executive Directors, and Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi as independent non-executive Directors.*